Skip to main content

Inside Kineta's plans after unveiling reverse merger deal

Kineta, a Seattle-based biotech, announced plans to go public through a reverse merger with Boston-based Yumanity. The deal could offer Kineta a major boost for its drug development pipeline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.